Congenital amegakaryocytic thrombocytopenia, abbreviated CAMT, is a rare autosomal recessive bone marrow failure syndrome marked by severe thrombocytopenia, which can progress to aplastic anemia and leukemia. It usually shows as a low platelet count in the first month of life or before birth, with petechiae, bleeding in the brain, recurrent rectal bleeding or lung hemorrhage. It is believed to be caused by mutations in the MPL gene, which codes for the thrombopoietin receptor. Diagnosis is by bone marrow biopsy, and it is often first suspected to be fetal and neonatal alloimmune thrombocytopenia. Treatment is mostly supportive, with repeated platelet transfusions, and hematopoietic stem cell transplantation is the only known cure. This entry is a reference record and not medical advice.
Facts
Classification
Communicable or Non-communicable Transmission Route Causative Agent
Causative Agent (category) Prevalence Band Sources
1. National Cancer Institute (NCI Thesaurus): Congenital amegakaryocytic thrombocytopenia - NCI Thesaurus concept C115207
National Cancer Institute (NCI Thesaurus)DefinitionQuote, Definition
A rare, autosomal recessive inherited disorder caused by mutation in the c-Mpl gene.
View the Source 2. Congenital amegakaryocytic thrombocytopenia (Wikipedia)
Lead section
The cause of CAMT is believed to be mutations in the MPL gene
Lead
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare autosomal recessive bone marrow failure syndrome characterized by severe thrombocytopenia, which can progress to aplastic anemia and leukemia.
View the Source3. Orphadata (Orphanet): Orphadata: Epidemiology of rare diseases (en_product9_prev)
Orphadata (Orphanet)ORPHA:3319Quote, ORPHA:3319
Prevalence at birth Value and class 1-9 / 1 000 000
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.